Related Experiment Video
Updated: Jun 8, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Treament of bechcet's disease.
L K Kamat1, M F Miranda, V L Rege
1Department of Medicine and Department of Dermatology, Venereology and Leprology, Goa Medical Gollege, Bambolim Complex, Goa -403202, India.
Indian Journal of Dermatology, Venereology and Leprology
|October 16, 2010
Summary
This case study shows dapsone can effectively maintain remission in Behcet's disease, even after initial corticosteroid treatment. Dapsone provided a viable alternative when high-dose corticosteroids were not tolerated.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Behcet's disease is a rare multisystem inflammatory disorder.
- Corticosteroids are a common initial treatment but often require high maintenance doses.
- Long-term corticosteroid use is associated with significant side effects.
Purpose of the Study:
- To present a case of Behcet's disease managed with a novel treatment approach.
- To evaluate the efficacy of dapsone as a steroid-sparing agent in Behcet's disease.
- To highlight dapsone as a potential maintenance therapy.
Main Methods:
- Initial treatment with corticosteroids for Behcet's disease.
- Addition of dapsone due to high corticosteroid dosage requirements.
- Maintenance therapy with dapsone alone after successful initial management.
Main Results:
- The patient achieved remission of Behcet's disease symptoms.
- Dapsone monotherapy successfully maintained remission.
- Substitution of corticosteroids with dapsone was necessitated by high maintenance doses.
Conclusions:
- Dapsone can be an effective monotherapy for maintaining remission in Behcet's disease.
- Dapsone offers a steroid-sparing alternative for patients requiring high-dose corticosteroids.
- This case suggests dapsone's utility in long-term Behcet's disease management.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...